Birth Control News and Research

RSS

Study compares costs of immediate birth control implant insertion with costs of unintended pregnancy

Women who have just given birth are often motivated to prevent a rapid, repeat pregnancy. For those who prefer a contraceptive implant, getting the procedure in the hospital immediately after giving birth is more cost-effective than delaying insertion to a 6-8 week postpartum visit, according to a new study by Yale School of Medicine researchers.

10 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Mayo Clinic provides expert guidance on fertility, conception

With Mother's Day being May 10 and May being Women's Health Month, Mayo Clinic offers expert guidance on fertility and conception.

7 May 2015

Common diabetes medication causes intersex in fish

A medication commonly taken for Type II diabetes, which is being found in freshwater systems worldwide, has been shown to cause intersex in fish -male fish that produce eggs.

27 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Study compares cost, benefits, complications of uterine-sparing treatments for fibroids

The relative cost, benefits, and complications of three minimally invasive techniques for reducing or eliminating symptomatic uterine fibroids are being compared in women who don't have cancer and want to preserve their uterus.

30 Mar 2015

Penn State surgeon provides guidelines for diagnosis, management of endometriosis

Endometriosis is difficult to diagnose, with women often being told for years that they are experiencing their 'normal period.' According to the Endometriosis Foundation of America, it affects one in ten women.

30 Mar 2015

New book focuses on life events resulting in teen motherhood

If Diane could reverse time, she never would have slammed the door--an act of teen frustration and ongoing family conflict that finally got her kicked out of her mother's house.

25 Mar 2015

Migraine headaches with auras may increase risk of stroke

People who suffer migraine headaches with auras are at roughly double the risk of suffering the most common type of stroke.

25 Mar 2015

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.

4 Mar 2015

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria.

23 Feb 2015

Catholics for Choice calls on Pope Francis to open childcare facilities in Vatican City

Today, in light of Pope Francis' comments that he believes "not having children is a selfish choice,"Catholics for Choice suggests that the pope, cardinals, bishops and priests that make up the citizens of Vatican City consider opening and running childcare facilities for the women in the world to give the hierarchy some hands-on experience.

12 Feb 2015

Study: IUDs, contraceptive implants remain highly effective one year beyond approved duration of use

New research indicates that hormonal intrauterine devices (IUDs) and contraceptive implants remain highly effective one year beyond their approved duration of use, according to a study at Washington University School of Medicine in St. Louis.

6 Feb 2015

Providing knowledge about contraception can significantly improve use of isotretinoin

Providing women who take a powerful acne drug with a fact sheet about contraception while visiting the dermatologist can significantly improve their awareness of the most effective birth control options and may prevent unintended pregnancies and birth defects that can be caused by the drug, according to a University of Pittsburgh School of Medicine study published Feb. 4 in the journal JAMA Dermatology.

5 Feb 2015

Childbearing women who take painkillers may face increased risk of birth defects

More than one-fourth of privately-insured and one-third of Medicaid-enrolled women of childbearing age filled prescriptions for opioid-based (narcotic) painkillers between 2008 and 2012, according to a new analysis published today by the U.S. Centers for Disease Control and Prevention in its Morbidity and Mortality Weekly Report (MMWR).

23 Jan 2015

Research breakthrough in understanding mosquito reproductive process

Diseases transmitted by mosquitoes have contributed to the death and suffering of millions throughout human history, earning the mosquito the title as the world's most dangerous animal. Even today, several devastating mosquito-borne diseases (such as malaria, dengue fever and West Nile virus) continue to rage.

21 Jan 2015

Injectable hormonal contraceptive appears to increase HIV risk in women

Women using depot medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera or the birth control shot, have a moderately increased risk of becoming infected with HIV, a large meta-analysis of 12 studies involving more than 39 500 women published in The Lancet Infectious Diseases has found. Other forms of hormonal contraception, including oral contraceptive pills, do not appear to increase this risk.

12 Jan 2015

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014